2-[((3,4-dimethoxyphenyl)carbonyl)amino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile | 313273-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[((3,4-dimethoxyphenyl)carbonyl)amino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile
• 英文别名: N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3,4-dimethoxybenzamide
• CAS: 313273-94-8
• 化学式: C₁₈H₁₈N₂O₃S
• 分子量: 342.419
• InChiKey: CKPZAXYMRMUGRU-UHFFFAOYSA-N

物化性质

• 沸点：
  477.6±45.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  99.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  环己酮 在 sulfur 、 二乙胺 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-[((3,4-dimethoxyphenyl)carbonyl)amino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile
  参考文献：
  名称：

  设计和合成针对肝丙酮酸激酶的新型 JNK 抑制剂，用于治疗非酒精性脂肪肝和肝细胞癌

  摘要：

  非酒精性脂肪性肝病 (NAFLD) 包括多种肝脏疾病，包括肝细胞癌 (HCC)，且尚未获得 FDA 批准的药物。肝脏丙酮酸激酶 (PKL) 是肝脏代谢通量和 ATP 生成的主要调节因子，是治疗 NAFLD 的潜在靶点。基于我们最近发现 JNK-5A 通过药物重新定位管道有效抑制 PKLR 表达，本研究旨在进一步提高其疗效。我们在分子对接研究的指导下合成了一系列具有针对性修饰的 JNK-5A 类似物。评估了这些化合物对人 HepG2 细胞系中 PKL 表达、细胞活力、三酰甘油 (TAG) 水平以及脂肪变性相关蛋白表达的活性。随后，评估了这些化合物在降低 TAG 水平和毒性方面的功效。化合物 (SET-151) 和 (SET-152) 被证明在降低 HepG2 中 TAG 水平方面最有效（11.51 ± 0.90 % 和 10.77 ± 0.67 %），并且毒性较低（61.60 ± 5.00 %

  DOI：

  10.1016/j.bioorg.2024.107425

文献信息

• Cell migration inhibiting compositions and methods and compositions for treating cancer
  申请人：Edwards L. David

  公开号：US20060128742A1

  公开（公告）日：2006-06-15

  Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

  本文提供了治疗癌症患者的方法。该方法可包括向患者施用细胞迁移抑制剂和化疗药物，以抑制癌细胞的迁移。抑制细胞迁移可增加细胞分裂。这样，由于细胞分裂增加，细胞迁移抑制剂和化疗剂联合使用的疗效可能比单独使用化疗剂的疗效更好。细胞迁移抑制剂可包括本文所述的任何抑制剂。例如，细胞迁移抑制剂可以是分子量小于约 700 的有机分子、单克隆抗体或天然产物。
• Synthesis and Pharmacological Characterization of 2-(Acylamino)thiophene Derivatives as Metabolically Stable, Orally Effective, Positive Allosteric Modulators of the GABA_B Receptor
  作者：Claudia Mugnaini、Valentina Pedani、Angelo Casu、Carla Lobina、Alberto Casti、Paola Maccioni、Alessandra Porcu、Daniela Giunta、Stefania Lamponi、Maurizio Solinas、Stefania Dragoni、Massimo Valoti、Giancarlo Colombo、Maria Paola Castelli、Gian Luigi Gessa、Federico Corelli

  DOI：10.1021/jm400144w

  日期：2013.5.9

  Two recently reported hit compounds, COR627 and COR628, underpinned the development of a series of 2-(acylamino)thiophene derivatives. Some of these compounds displayed significant activity in vitro as positive allosteric modulators of the GABA(B) receptor by potentiating GTP gamma S stimulation induced by GABA at 2.5 and 25 mu M while failing to exhibit intrinsic agonist activity. Compounds were also found to be effective in vivo, potentiating baclofen-induced sedation/hypnosis in DBA mice when administered either intraperitoneally or intragastrically. Although displaying a lower potency in vitro than the reference compound GS39783, the new compounds 6, 10, and 11 exhibited a higher efficacy in vivo: combination of these compounds with a per se nonsedative dose of baclofen resulted in shorter onset and longer duration of the loss of righting reflex in mice. Test compounds showed cytotoxic effects at concentrations comparable to or higher than those of GS39783 or BHF177.
• CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Avolix Pharmaceuticals

  公开号：EP1576110A2

  公开（公告）日：2005-09-21
• EP1576110A4
  申请人：——

  公开号：EP1576110A4

  公开（公告）日：2007-11-07
• US7012100B1
  申请人：——

  公开号：US7012100B1

  公开（公告）日：2006-03-14